Chapter 10: Problems of the Breast

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Usually when we talk about a medical diagnosis,

there's this expectation of mechanical precision, you know, like you suspect a broken arm, the x -ray shows a jagged white line right through the radius and the provider just points and says, yep, there it is.

Right.

It's very binary, broken or not broken, which is very comforting for a clinician.

We prefer things clean and categorizable.

Exactly.

But stepping into the world of women's health and specifically breast pathophysiology,

I mean, you kind of have to throw that binary diagnostic comfort right out the window.

Oh, absolutely.

Suddenly we are looking at a diagnostic landscape that is incredibly murky.

We're dealing with a whole spectrum of cellular changes that are constantly being manipulated by fluctuating hormones, shifting genetics and well, age.

It is the absolute definition of diagnostic muddy waters and navigating those waters requires a highly developed clinical eye because a nurse cannot afford to look at breast tissue as just a single anatomical structure.

You have to view it as a dynamic hormone responsive organ where the between a normal variance in a lethal pathology is sometimes like microscopic.

Yeah.

So for the nursing students listening, you know, whether you are prepping for a clinical rotation or grinding for your next pathophysiology exam, our mission today is to give you that clinical eye.

We are going straight into a deep dive of breast abnormalities and we are relying entirely on the clinical frameworks laid out in chapter 10 of maternity and women's health care.

Yep.

The 13th and this isn't just about memorizing facts.

You know, it's about building the clinical reasoning to understand why these conditions happen, how they present in triage and what we actually do about them.

And the best place to build that framework is at the baseline before we can even begin to recognize breast cancer.

We have to understand anatomic variances and the normal spectrum of cellular changes because well, not every physical difference is a disease.

That makes sense.

Let's look at the extremes of physical development first.

So micromastia, which is profound underdevelopment and macromastia or breast hyperplasia where a patient has very large, heavy, pendulous breasts.

Macromastia isn't just like a cosmetic variance, right?

No, not at all.

The clinical relevance of macromastia is entirely functional.

These patients suffer from severe chronic neck, shoulder, and back pain.

Wow.

Yeah.

They get deep grooving in their shoulders from bra straps and persistent skin breakdown beneath the breast folds.

For them, a breast reduction surgery is a massive improvement in their health -related quality of life.

But the nursing agitation role here is heavy, right?

Because reduction surgery isn't without functional costs.

Right.

Exactly.

Like if a patient wants to breastfeed in the future, we have to counsel them that physically removing that much glandular tissue and repositioning the nipple almost guarantees severed lactiferous ducts and nerve damage.

It drastically reduces the chances of successful lactation.

And actually, speaking of anatomical quirks along the milk lines, you'll occasionally see supernumerary nipples.

Oh, the extra nipples.

Yep.

They develop anywhere along the embryonic milk line, stretching from the axilla all the way down to the groin.

They can sometimes swell during menstruation or pregnancy, but functionally.

They require absolutely no treatment unless they become a severe cosmetic bother to the patient.

Okay.

So those are structural variances.

But the real complexity begins when we zoom in on the cellular level to look at benign breast disorders.

The clinical text categorizes these benign lesions strictly by how much they increase a patient's risk of eventually developing breast cancer.

Right.

Think of it as a spectrum of cellular behavior.

At the lowest end, you have nonproliferative lesions like simple fluid -filled cysts.

The cells aren't multiplying.

They're just reacting.

I always picture nonproliferative cysts like a blister.

It's fluid trapped in a tight space.

It might be tender.

It might be annoying, but it's contained and it isn't actively building a malignant structure.

So it carries no increased risk for breast cancer.

That is a highly accurate way to visualize it.

Now, moving up the risk spectrum, we find proliferative lesions without

Okay.

So they are multiplying now.

Exactly.

These are conditions where the cells are multiplying more than normal, building things like fibrodinomas or interductal papillomas.

But the cells themselves still look completely normal under a microscope.

They carry a mild to moderate increase in cancer risk.

But the clinical red flag, like the finding that fundamentally alters the trajectory of a patient's care, is a proliferative lesion with atypical hyperplasia.

This includes atypical ductal hyperplasia, ADH, and atypical lobular hyperplasia, ALH.

The mechanism here is what matters.

Atypical hyperplasia means the cellular factory has basically fired its quality control manager.

Oh, wow.

That's a good way to put it.

Yeah.

The breast tissue isn't just overproducing cells.

It is overproducing flawed mutated cells.

A pathology report showing atypia means that patient now has a four to five times greater risk of developing breast cancer.

Okay.

Let's unpack this.

If breast cells are on a highway, non -proliferative lesions are just parked cars.

But atypical hyperplasia, that's a cellular yellow light flashing right before a major intersection.

What's fascinating here is how that pathology report directly dictates a nurse's risk assessment strategy.

We go from basic education to highly aggressive surveillance, potentially discussing frequent MRIs and chemo prevention.

Because that patient is now standing right on the precipice of malignancy.

Exactly.

Let's apply this clinically.

Say a 25 -year -old patient comes into the clinic highly anxious because she felt a lump in her breast.

We know about the cellular risks, but how does a nurse differentiate a simple cyclical change from a distinct structural tumor during triage?

Well, we rely heavily on the contrast between timing and palpation characteristics.

The text breaks down table 10 .1 comparing these masses.

The most common benign issue by far is which isn't really a disease, right?

Right.

It's not a disease.

It's an exaggerated physiologic response to the normal monthly surge of ovarian hormones.

Because estrogen and progesterone tell the breast tissue to swell and prepare for potential lactation.

So on an exam, fibrocystic changes present as bilateral cyclical nodular lumpiness.

The classic textbook description is that the breast tissue feels like peas.

Yep.

Like a bag of peas.

And the pain and swelling peak roughly a week before menstruation and rapidly subside a week after.

So how do we treat that?

We treat it conservatively.

We advise a highly supportive raw NSAIDs for the inflammation and sometimes oral contraceptives to smooth out those aggressive hormonal peaks and valleys.

Interestingly, dietary changes make a huge impact.

Like what kind of changes?

Reducing dietary fat helps, but specifically cutting out mesothazanthines, which means coffee, tea, colas, and chocolate that can significantly reduce the fibrotic tissue stimulation.

Okay.

So contrast that cyclical bilateral lumpiness with a fibrodinoma.

Table 10 .1 makes this really clear.

If you palpate a fibrodinoma, it is entirely different.

It presents as a solid, firm, smooth, solitary mass.

And it's highly mobile.

It literally slips right under your fingers.

Yes.

And most importantly, its size is structurally fixed.

It is not influenced by the menstrual cycle at all.

Because the fibrodinoma is a localized overgrowth of stromal and epithelial tissue, it's completely disconnected from the monthly hormonal roller coaster.

Got it.

Now beyond lumps, we also have to assess reactive inflammatory lesions.

The text highlights a crucial distinction between mammary duct ectasia and actual infectious mastitis.

Right.

Mammary duct ectasia usually strikes in the perimenopausal period.

The path of physiology is fascinating.

The ducts behind the nipple abnormally dilate, fill with cellular debris and secretions, and eventually leak that irritating fluid into the surrounding breast tissue.

Which triggers a massive inflammatory cascade.

Exactly.

You'll see a thick, sticky discharge.

And what stands out epidemiologically is that this condition has a remarkably high recurrence rate in smokers, likely because systemic toxins from cigarette smoke damage the ductal epithelium.

Wait, if a patient comes in with a red, hot breast, how do we differentiate that sterile inflammatory process from a true infection?

A true infection like cellulitis presents with hot, red, thickened skin and requires immediate antibiotics, especially given the prevalence of MRSA.

Or you might see lactational mastitis, which is almost exclusively seen during pregnancy or postpartum breastfeeding.

Okay, another assessment finding that causes massive patient anxiety is nipple discharge.

We have to separate the physiologic from the pathologic.

Right.

Physiologic discharge is termed galacturia.

It presents as a bilateral, milky, sticky discharge in a woman who is neither pregnant nor breastfeeding.

So it's a systemic issue.

Yes.

It happens because of elevated prolactin levels circulating in the blood, which can be triggered by underlying thyroid disorders, or incredibly common medications like tricyclic antidepressants and oral contraceptives.

Okay, but the pathologic red flag is a discharge that is unilateral, spontaneous, and cirrus, or frankly, bloody.

That clinical presentation heavily points toward an

Exactly.

A papilloma is a benign tumor growing inside the terminal nipple ducts.

As it grows, it erodes the delicate ductal tissue, causing it to bleed or leak.

Even though the tumor itself is benign, its location in association with localized malignancy risk means surgical excision is the standard recommendation.

Wow.

Okay.

So when we combine benign atypical hyperplasia with broader lifestyle and genetic factors, we cross the bridge from assessing harmless lumps into the urgent realm of assessing true breast cancer risk.

Yeah, the ideology of breast cancer is this massive mosaic of statistical data points.

The non -modifiable risk factors start with age and genetics specifically inheriting mutated BRCA1 or BRCA2 genes, which normally function as tumor suppressors.

But the most insidious non -modifiable factor is the length of a woman's unopposed estrogen exposure.

If we connect this to the bigger picture, estrogen is the primary fuel for many breast changes, which is why a patient's reproductive timeline is the ultimate map of their breast cancer risk.

Estrogen is a mitogen.

It acts as a chemical signal, telling breast cells to actively divide and multiply.

And the more cellular divisions that occur over a lifetime, the higher the mathematical probability that a genetic copying error will occur, leading to cancer.

Which perfectly explains why early menarche starting periods before age 12 or late menopause, ending them after age 55, are such huge risk factors.

The breast tissue is being bathed in those monthly estrogen spikes for a significantly longer portion of the patient's life.

The modifiable factors tie directly into this hormonal mechanism too, like nulliparity or having a first child after age 30 increases risk because the patient misses out on the prolonged resting phase that pregnancy and lactation provide the breast tissue.

And postmenopausal obesity is another major modifiable factor because fat tissue actively synthesizes peripheral estrogen, feeding any microscopic tumors that might be forming.

To make sense of all these overlapping variables, clinicians use the breast cancer risk assessment tool, widely known as the Gale model.

The text outlines this in box 10 .1.

It basically calculates a patient's individualized risk percentage by crunching their age, family history, age at first live birth, and the number of previous breast biopsies they've endured.

For patients whose Gale model percentage places them in the high -risk category, we introduce chemo prevention.

We preemptively prescribe medications to block estrogen from fueling potential tumors.

We will dive deep into the specific mechanisms of those meds in our pharmacology section.

But regarding prevention and screening, there's been a massive paradigm shift.

The American Cancer Society formally stopped recommending routine monthly breast self -examinations as a screening tool.

Right.

The clinical data revealed that rigid monthly exams were driving immense patient anxiety and triggering thousands of unnecessary invasive biopsies for benign cysts without actually reducing breast cancer mortality rates.

However, the nursing priority shifts to teaching breast self -awareness.

Women very frequently discover malignant lumps organically during normal daily activities like washing in the shower or getting dressed.

They need to be intimately familiar with the baseline topography of their own body so they can immediately recognize when something structural deviates from their normal.

Exactly.

Now, once a patient does find a suspicious mass and the interprofessional team steps in, we rely on staging and pathology to understand exactly what is happening at the tissue level.

The first anatomical distinction is in situ versus invasive.

In situ means the cancer is still perfectly confined inside the basement membrane of the milk duct or the lobule.

Invasive means the tumor has aggressively broken through that membrane and invaded the surrounding fatty stroma where it now has access to blood vessels and lymphatic channels.

The vast majority, around 80 percent of cases, are invasive ductal carcinoma.

Because it originates in the dust and builds a hard fibrotic stroma, it presents clinically as a unilateral rock hard non -mobile mass.

And what about invasive lobular carcinoma?

Well, that originates in the milk producing lands and it is much stealthier.

It doesn't always form a hard lump, making it frequently non -palpable and much harder to detect on a standard mammogram.

It also carries a notoriously higher risk of presenting bilaterally in both breasts.

We also have to watch for rare but incredibly aggressive forms.

Inflammatory breast cancer is notorious for being misdiagnosed by primary care providers as routine mastitis.

The pathophysiology of inflammatory breast cancer is what drives its unique appearance.

The cancer cells rapidly break out and physically block the lymphatic channels draining the breast.

Oh, so the fluid backs up.

Yes, the fluid backs up, causing the breast to become firm, red, and swollen.

The swelling around the hair follicles creates a pitted, dimpled appearance called peau d 'orange because the skin literally resembles the rind of an orange.

Another rare presentation is Paget disease, which originates in the lactiferous ducts but migrates outward to infiltrate the skin of the nipple and areola.

It presents as persistent oozing, crusting, scaling, and bleeding that just won't heal with topical treatments.

Diagnosing the exact nature of these tumors requires advanced screening.

Mammography remains the gold standard, but for younger women or any patient with radiographically dense breast tissue,

standard 2D mammography struggles to penetrate the tissue.

We utilize 3D mammography or tool synthesis, which takes digital slices through the dense tissue.

An ultrasound is the perfect adjunct tool because sound waves easily differentiate a benign fluid filled cyst from a solid, potentially malignant mass.

MRI is reserved for extremely high risk patients or those with existing silicone implants that obscure mammogram views.

We also must contextualize these screening modalities within systemic realities.

The cultural considerations box in the text explicitly highlights the disparities in breast cancer outcomes among

The data is glaring.

Minority women frequently face higher breast cancer mortality rates, driven by systemic barriers including lack of access to advanced screening, gaps in health literacy, and implicit bias from healthcare providers that delays diagnosis.

The nursing mandate here is to actively develop culturally sensitive community -based education programs to dismantle those barriers.

Absolutely.

Now, when a diagnosis is confirmed, we stage the cancer using the TNM system tumor size, node involvement, and metastasis.

Table 10 .3 lays this out.

But anacomical staging is only half the battle.

Modern oncology relies heavily on molecular staging by identifying receptor status.

Here's where it gets really interesting.

We look for estrogen receptors, progesterone receptors, and the arytenu protein.

Think of receptors like highly specific locks on the door of the cancer cell.

If a tumor is ER positive, it means circulating estrogen acts as the key, turning that lock and telling the cancer to aggressively replicate.

Right.

If the tumor has those hormone locks, we categorize it as a luminal type, which generally grows slower and responds beautifully to hormone -blocking medications.

We also test for a proliferation marker called CHI6 -7, which gives us a literal mathematical percentage of exactly how many tumor cells are actively dividing at any given moment.

But the most dangerous pathology report is a triple negative tumor.

It lacks estrogen receptors, lacks progesterone receptors, and lacks the HER2 receptor.

The tumor has absolutely no locks that we can easily target with specialized hormone keys.

It relies entirely on aggressive systemic chemotherapy, making it incredibly difficult to treat.

Once the tumor is biologically staged, the first line of defense is usually surgical excision.

The surgical approach is dictated entirely by the tumor's size, location, and the patient's genetic risk.

Patients generally face two distinct pathways.

The first is breast conserving surgery or a lumpectomy.

The surgeon removes only the tumor and a thin rim of healthy margin tissue.

But choosing a lumpectomy comes with an absolute requirement.

The patient must undergo follow -up radiation therapy to clean up any microscopic stray cells left behind in the remaining breast tissue.

The alternative is a mastectomy, which ranges from total removal of the breast tissue to modified radical approaches, or skin and nipple sparing techniques designed to facilitate immediate cosmetic reconstruction.

But because breast cancer is notorious for shedding cells into the lymphatic drainage system, the surgeon must investigate the axillary lymph nodes under the arm.

Historically, surgeons performed an axillary lymph node dissection, indiscriminately stripping out nodes.

And the collateral damage of an axillary dissection is severe chronic lymphedema.

Without those nodes, lymphatic fluid permanently backs up into the arm, causing massive debilitating swelling.

To avoid that, the modern standard is the sentinel lymph node biopsy.

The surgical team injects a blue dye and a radioactive tracer directly into the tumor site.

They watch the lymphatic channels to see which single node absorbs the dye first.

That node is the sentinel, the first guard at the gate.

Right.

And if they extract that single blue node and the pathology shows it is completely clear of cancer, they leave the rest of the axillary nodes safely intact, drastically preserving the patient's lymphatic function.

For patients who do undergo mastectomies, reconstruction is a major clinical focus.

Table 10 .4 compares reconstructive options.

They can opt for implants using silicone or saline or complex flat procedures like the tram or latissimus dorsi flaps.

These procedures harvest the patient's own tissue and muscle from their abdomen or back and tunnel it up to rebuild the breast mount.

The flat procedures provide a very natural result, but nurses must monitor for significant donor site morbidity, including severe abdominal weakness or the development of hernias where the muscle was removed.

Timing is also critical here.

Right, wait.

If a patient can wake up with a reconstructed breast immediately, why would anyone ever choose a delayed reconstruction?

It hinges on the need for post -mastectomy radiation.

Radiation therapy is incredibly harsh on microvasculature.

If a surgeon builds a delicate, newly reconstructed tissue flap and then blasts it with radiation, the compromised blood vessels will fail.

The tissue can become necrotic, severely scarred, and permanently deformed.

In those cases, delaying reconstruction until radiation is complete is the only clinically safer choice.

Speaking of post -surgical clinical choices, there is an absolute non -negotiable NCLE -X level clinical alert regarding patients who have undergone any form of axillary node dissection.

Yes.

This is a vital pro tip for the floor.

It is an absolute contraindication to ever take a blood pressure, draw blood, or start an IV on the arm of the affected side.

The lymphatic drainage in that arm is permanently compromised.

A tight tourniquet or a simple needle stick infection can overwhelm the remaining lymph vessels and trigger irreversible, catastrophic lymphedema.

You must aggressively protect that arm.

That is so important.

Now, surgery successfully removes the macroscopic visible threat, but because breast cancer is a systemic disease, we must hunt down the microscopic threats using adjuvant systemic therapies, essentially radiation in pharmacology.

Radiation can be delivered externally over several weeks or internally via brachytherapy.

In brachytherapy, a deflated balloon is surgically inserted directly into the empty cavity left by a lumpectomy.

The balloon is inflated with saline, and radioactive seeds are fed into the balloon to irradiate the immediate tissue bed from the inside out, usually for just five days.

The pharmacology piece centers on the medication guides for hormonal therapy.

These agents manipulate the systemic environment to starve the cancer.

First, we have Tamoxifen, which belongs to a class called Selective Estrogen Receptor Modulators, or CIRMS.

The word selective is the key to understanding how Tamoxifen works.

In breast tissue, Tamoxifen acts as an antagonist.

It behaves like a broken key jammed into the estrogen receptor lock.

It blocks circulating estrogen from attaching and feeding the tumor.

It is highly effective for both

postmenopausal women.

However, in other parts of the body, Tamoxifen acts as an estrogen agonist.

It actually turns the lock.

In the uterus, it mimics estrogen, causing endometrial proliferation, which carries a highly dangerous risk for developing endometrial cancer.

In the liver, it stimulates clotting factors, creating a severe risk for deep vein thrombosis.

So, patients on Tamoxifen require rigorous nursing surveillance.

They need regular function tests, frequent eye exams to monitor for drug -induced cataracts, and education to report any abnormal vaginal bleeding instantly as it could signal endometrial malignancy.

Right.

A related CIRM is Riloxafine, but this is prescribed strictly for postmenopausal women.

Riloxafine acts as an estrogen agonist in the bones, actively preventing osteoporosis while still blocking estrogen in the breast tissue.

It does not carry the same severe uterine cancer risk as Tamoxifen, but the risk for fatal DVTs and strokes remains incredibly high.

But wait, if a patient is postmenopausal, why do they sometimes get a completely different class of drug, like Letrozole, an aromatase inhibitor?

If they are postmenopausal, their ovaries have permanently shut down.

Why do they need a drug to block estrogen production?

That mechanism trips up a lot of clinicians.

While the ovaries have stopped producing estrogen, the postmenopausal body relies on a backup generator.

Fat and muscle tissues contain an enzyme called aromatase.

Aromatase actively converts circulating adrenal androgen's male hormones into small, continuous amounts of peripheral estrogen.

I see.

Letrozole specifically targets and destroys that backup generator.

It blocks the aromatase enzyme, completely prevents the peripheral conversion of androgens to estrogen.

Leaving the patient utterly starved of estrogen.

And because estrogen is the primary protector of bone density in women, wiping it out causes immense severe bone pain and a staggering risk for rapid onset osteoporosis.

Nursing care requires aggressive monitoring of bone density scans and coaching the patient through weight -bearing exercise regimens.

Wow.

For those highly aggressive, triple negative tumors that ignore hormone therapies entirely, we rely on cytotoxic chemotherapy.

The side effects are brutal and systemic.

Neutropenia, alopecia, profound nausea.

There's a vital piece of nursing education regarding chemotherapy.

The chemical agents are highly teratogenic.

They will cause catastrophic fetal abnormalities.

Women receiving chemotherapy must be educated to use strictly non -hormonal birth control methods.

Right.

Because even if the chemotherapy induces amenorrhea and their periods completely stop, the ovaries can still sporadically release an egg.

They can still get pregnant without ever having a period, making barrier methods utterly essential.

The clinical text also requires us to adapt our care for special populations.

Young premenopausal women often face the most biologically aggressive tumors, forcing them into heart -wrenching rapid -fire decisions about freezing embryos or preserving ovarian tissue before the cytotoxic drugs permanently destroy their fertility.

Conversely, when treating women over 65, the oncology team must look past chronological age.

A comprehensive geriatric assessment is required, focusing heavily on

baseline organ health and social support to determine if their bodies can physically withstand the toxicity of the proposed treatments.

This raises an important question.

How do we support the whole patient?

Because once the acute medical treatments are complete, the patient's journey to healing truly begins.

Nursing interventions pivot from acute crisis management to helping the patient transition from the sick role into a long -term survivor.

In the immediate post -operative phase, priority number one is protecting lymphatic return.

The nurse must elevate the patient's affected arm above the level of the right atrium to let gravity assist the compromised lymph vessels.

We also manage the Jackson -Pratt or Himovac drains, emptying and meticulously recording the output every eight hours to ensure fluid isn't pooling under the surgical flaps.

Education transitions immediately into self -management.

To prevent the chest, wall, and shoulder from freezing into painful contractures, we teach specific progressive arm exercises.

The arm exercises after breast surgery box shows the wand exercise, where the patient uses a broom handle grasped in both hands to gently push the affected arm upward.

We teach elbow winging and having the patient use their fingers to slowly climb a wall, stretching the healing tissue and actively promoting lymphatic drainage.

Emphasize wearing loose clothing and pinning drains safely.

Long -term survivorship presents an entirely new set of chronic challenges.

Think about vasomotor symptoms.

The severe, debilitating hot flashes caused by plunging into chemical menopause via hormone blockers.

Because their cancer was hormone receptor positive, we absolutely cannot give them traditional hormone replacement therapy to ease the symptoms that would literally feed any remaining cancer cells.

Instead, nurses must manage these symptoms using neuroactive medications like Gabapentin or rely on cognitive behavioral therapy.

Survivors also battle chemotherapy -induced sarcopenic obesity.

The toxic drugs cause a rapid simultaneous loss of lean muscle mass and an aggressive gain of adipose fat tissue, fundamentally altering their metabolism and physical strength.

And perhaps the most dangerous shadow lurking in survivorship is cardiotoxicity.

Chemotherapy agents like anthracyclines and taxanes are highly toxic to the myocardium.

Years down the line, these survivors can develop irreversible congestive heart failure directly caused by the drugs that save their lives.

They require intense ongoing cardiac monitoring.

The sheer complexity of these overlapping issues is why the psychosocial and logistical support provided by nurses is just as critical as the clinical wound care.

We rely heavily on oncology nurse navigators to coordinate this massive web of specialists and community resources like the Reach to Recovery program, which steps in to provide temporary prostheses and invaluable peer -to -peer emotional support from fellow survivors.

The path from a suspicious lump to long -term survivorship is terrifying and long, but it is the meticulous assessment, education, and vigilance of the nursing team that makes navigating that journey possible for the patient.

We have covered immense ground today, tracking the cellular breakdown of atypical hyperplasia all the way through the precise physiological mechanisms of lumpectomies, sentinel nodes, and aromatease inhibitors.

You've got this.

Take a deep breath, review your med guides with these mechanisms in mind, and trust your expanding clinical reasoning.

Thank you for joining us for this session.

Thank you for studying with the last minute lecture team, but before you close your notebooks, we want to leave you with a final concept to mull over.

Something to think about.

We know that modern breast cancer treatments are incredibly effective at saving lives, but we also know they create massive systemic shockwaves, plunging patients into premature menopause, inducing sarcopenic obesity, and threatening long -term cardiotoxicity.

Given all that, how might your specific role as an oncology nurse evolve in the coming years?

Will tomorrow's cancer care require you to be just as much an expert in preventative cardiology and metabolic exercise physiology as you are in tumor pathology?

That is a fascinating horizon.

It really is.

Something to think about before your next clinical shift.

We'll see you next time.